8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported):  July 23, 2010(July 20, 2010)
                                                   ----------------------

                         COMPETITIVE TECHNOLOGIES, INC.
             (Exact name of registrant as specified in its charter)

         Delaware                       001-08696              36-8664428
- --------------------------------------------------------------------------------
(State or other jurisdiction     (Commission File Number)     (IRS Employer
    of incorporation)                                        Identification No.)

     777 Commerce Drive, Fairfield, Connecticut                  06825
- --------------------------------------------------------------------------------
       (Address of principal executive offices)               (Zip Code)

Registrant's telephone number, including area code: (203) 368-6044
                                                    --------------

                                      n/a
   (Former name, former address and former fiscal year, if changed since last
                                    report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



ITEM  3.01.  NOTICE  OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE
OR  STANDARD;  TRANSFER  OF  LISTING

On  July  20,  2010,  Competitive  Technologies,  Inc.  ("CTT" or the "Company")
received notice that the NYSE Amex (the Exchange) has postponed indefinitely the
delisting  hearing  it  had  scheduled  for July 22, 2010, pending review of the
final  completion  of  CTT's  sale  of two million shares of CTT common stock to
Crisnic  Fund.  The  fund raise will provide CTT capital to increase shareholder
equity  required  to  retain the Exchange listing, and to more aggressively sell
its  non-invasive  Calmare  Pain  Therapy Treatment device.   The transaction is
currently  being  funded following the July 14, 2010, date that the SEC declared
the  required  registration  statement  effective,  and CTT anticipates that the
final  closing  of  the  fund  raise  will  occur  shortly.

ITEM  8.01.  OTHER  EVENTS

On  July  21, 2010, CTT issued the press release attached herein as exhibit 99.1

ITEM  9.01.  EXHIBITS

99.1     Press  Release  dated  July  21,  2010.

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


COMPETITIVE TECHNOLOGIES, INC.
(Registrant)

Dated: July 23, 2010                         By: \s\John B. Nano
                                                 ---------------
                                             John B. Nano
                                             Chief Executive Officer

EX-99.1

Exhibit 99.1                                               For immediate release

               COMPETITIVE TECHNOLOGIES ANNOUNCES THAT NYSE AMEX
                        HAS POSTPONED DELISTING HEARING

FAIRFIELD,  CT  -  (JULY  21, 2010) - COMPETITIVE TECHNOLOGIES, INC. (NYSE AMEX:
CTT)  today  announced  that  the  NYSE  Amex  (the  Exchange)  has  postponed
indefinitely  the  delisting hearing it had scheduled for July 22, 2010, pending
review of the final completion of CTT's sale of two million shares of CTT common
stock  to  Crisnic  Fund.  The  fund  raise will provide CTT capital to increase
shareholder  equity  required  to  retain  the  Exchange  listing,  and  to more
aggressively sell its non-invasive Calmare  Pain Therapy Treatment device.   The
transaction is currently being funded following the July 14, 2010, date that the
SEC  declared the required registration statement effective, and CTT anticipates
that  the  final  closing  of  the  fund  raise  will  occur  shortly.

" We have worked hard to meet the Exchange's standards and will continue to work
to  maximize  shareholder value as we increase sales of our non-invasive Calmare
Pain  Therapy  Treatment  medical  device,"  said  John B. Nano, CTT's Chairman,
President,  and  CEO.

"Calmare  pain  therapy  is  the  only  highly  effective  treatment  for
chemotherapy-induced  peripheral  neuropathy (CIPN) without the harmful, adverse
side  effects  of narcotic pain killers," Mr. Nano continued.  "From the growing
body  of  evidence-based  patient outcomes we know that in addition to CIPN, our
Calmare  device  successfully  treats  chronic  neuropathic  and  oncologic pain
resulting  from  cancer,  phantom  limb syndrome, failed back surgery, sciatica,
spinal  stenosis,  shingles  and  other  maladies."

The  non-invasive  Calmare  pain  therapy device uses the biophysical "Scrambler
Therapy"  technology,  which  was  developed in Italy by CTT's client, Professor
Giuseppe  Marineo.  CTT's  partner,  GEOMC  Co.  Ltd.  of  Seoul,  Korea  is
manufacturing  the  Calmare  device,  which  has U.S. FDA clearance and European
Union  CE  Mark  clearance  for  sales.  For more information about Calmare Pain
Therapy  Treatment,  visit  www.CalmareTT.com.

ABOUT COMPETITIVE TECHNOLOGIES, INC.

Competitive Technologies, established in 1968, provides distribution, patent and
technology transfer, sales and licensing services focused on the needs of its
customers and matching those requirements with commercially viable product or
technology solutions.  CTT is a global leader in identifying, developing and
commercializing innovative products and technologies in life, electronic, nano,
and physical sciences developed by universities, companies and inventors.  CTT
maximizes the value of intellectual assets for the benefit of its customers,
clients and shareholders. Visit CTT's website: www.competitivetech.net
                                               -----------------------

Statements made about our future expectations are forward-looking statements and
subject to risks and uncertainties as described in our most recent Annual Report
on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27,
2009, and other filings with the SEC, and are subject to change at any time.
Our actual results could differ materially from these forward-looking
statements.  We undertake no obligation to update publicly any forward-looking
statement.

Direct inquiries to Johnnie D. Johnson, IR Services, LLC, Tel: 860.434.2465,
Email: jdjohnson@corpirservices.com.
       ----------------------------